BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 10485475)

  • 21. Mutations in exon 11 of the c-kit gene in a myogenic tumor and a neurogenic tumor as well as in gastrointestinal stromal tumors. Utility of c-kit mutation as a prognostic biomarker for gastrointestinal mesenchymal tumor.
    Yasuoka R; Sakakura C; Shimomura K; Fujita Y; Nakanishi M; Aragane H; Hagiwara A; Bamba M; Abe T; Yamagishi H
    Dig Surg; 2003; 20(3):183-91. PubMed ID: 12759497
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gastrointestinal stromal tumors with KIT mutations exhibit a remarkably homogeneous gene expression profile.
    Allander SV; Nupponen NN; Ringnér M; Hostetter G; Maher GW; Goldberger N; Chen Y; Carpten J; Elkahloun AG; Meltzer PS
    Cancer Res; 2001 Dec; 61(24):8624-8. PubMed ID: 11751374
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of KIT mutations in sporadic and familial gastrointestinal stromal tumors: therapeutic implications through protein modeling.
    Tarn C; Merkel E; Canutescu AA; Shen W; Skorobogatko Y; Heslin MJ; Eisenberg B; Birbe R; Patchefsky A; Dunbrack R; Arnoletti JP; von Mehren M; Godwin AK
    Clin Cancer Res; 2005 May; 11(10):3668-77. PubMed ID: 15897563
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity.
    Debiec-Rychter M; Wasag B; Stul M; De Wever I; Van Oosterom A; Hagemeijer A; Sciot R
    J Pathol; 2004 Apr; 202(4):430-8. PubMed ID: 15095270
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gastrointestinal stromal tumours.
    Miettinen M; Sarlomo-Rikala M; Lasota J
    Ann Chir Gynaecol; 1998; 87(4):278-81. PubMed ID: 9891765
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.
    Demetri GD
    Semin Oncol; 2001 Oct; 28(5 Suppl 17):19-26. PubMed ID: 11740803
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic and pathologic characteristics of gastrointestinal stromal tumors in extragastric lesions.
    Cho S; Kitadai Y; Yoshida S; Tanaka S; Yoshihara M; Yoshida K; Chayama K
    Int J Mol Med; 2006 Dec; 18(6):1067-71. PubMed ID: 17089009
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Frequent c-Kit gene mutations not only in gastrointestinal stromal tumors but also in interstitial cells of Cajal in surrounding normal mucosa.
    Ogasawara N; Tsukamoto T; Inada K; Mizoshita T; Ban N; Yamao K; Joh T; Itoh M; Tatematsu M
    Cancer Lett; 2005 Dec; 230(2):199-210. PubMed ID: 16297706
    [TBL] [Abstract][Full Text] [Related]  

  • 29. KIT exon 11 deletion-inversions represent complex mutations in gastrointestinal stromal tumors.
    Lasota J; Miettinen M
    Cancer Genet Cytogenet; 2007 May; 175(1):69-72. PubMed ID: 17498562
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Analysis of c-kit gene mutations in gastrointestinal stromal tumors].
    Hou YY; Sun MH; Tan YS; Wei YK; Lu XY; Zhang TM; Du X; Wang J; Zhu XZ
    Zhonghua Zhong Liu Za Zhi; 2004 Feb; 26(2):89-92. PubMed ID: 15059325
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical implications of C-kit gene mutation in patients with large gastrointestinal stromal tumors.
    Lin SC; Liu CL; Wang TI; Chang WS; Tzen CY; Huang MJ
    J Gastroenterol Hepatol; 2006 Oct; 21(10):1604-8. PubMed ID: 16928224
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Gastrointestinal stromal tumors carrying PDGFRalpha mutations occur preferentially in the stomach and exhibit an epithelioid or mixed phenotype].
    Wardelmann E; Pauls K; Merkelbach-Bruse S; Hrychyk A; Losen I; Hohenberger P; Büttner R; Pietsch T
    Verh Dtsch Ges Pathol; 2004; 88():174-83. PubMed ID: 16892550
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of GIST/GIPACT tumors by inmunohistochemistry and exon 11 analysis of c-kit by PCR.
    Bernet L; Zuñiga A; Cano R
    Rev Esp Enferm Dig; 2003 Oct; 95(10):688-91, 683-7. PubMed ID: 14588063
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors.
    Chen LL; Trent JC; Wu EF; Fuller GN; Ramdas L; Zhang W; Raymond AK; Prieto VG; Oyedeji CO; Hunt KK; Pollock RE; Feig BW; Hayes KJ; Choi H; Macapinlac HA; Hittelman W; Velasco MA; Patel S; Burgess MA; Benjamin RS; Frazier ML
    Cancer Res; 2004 Sep; 64(17):5913-9. PubMed ID: 15342366
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Effect of c-kit gene mutation on prognosis of gastrointestinal stromal tumor].
    Ma DL; Liu XH; Bai CG; Xie Q; Feng F
    Zhonghua Wai Ke Za Zhi; 2004 Feb; 42(3):140-4. PubMed ID: 15062057
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site.
    Antonescu CR; Viale A; Sarran L; Tschernyavsky SJ; Gonen M; Segal NH; Maki RG; Socci ND; DeMatteo RP; Besmer P
    Clin Cancer Res; 2004 May; 10(10):3282-90. PubMed ID: 15161681
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [c-Kit and PDGFRA mutations and clinico-morphological features of gastrointestinal stromal tumors].
    Beliakov IS; Anurova OA; Snigur PV; Tsyganova IV; Sel'chuk VIu; Mazurenko NN
    Vopr Onkol; 2007; 53(6):677-81. PubMed ID: 18416137
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Spectrum and prognostication of KIT and PDGFRA mutation in gastrointestinal stromal tumors.
    Tzen CY; Wang MN; Mau BL
    Eur J Surg Oncol; 2008 May; 34(5):563-8. PubMed ID: 17532173
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multiple gastrointestinal stromal tumors: Clinicopathologic and genetic analysis of 12 patients.
    Kang DY; Park CK; Choi JS; Jin SY; Kim HJ; Joo M; Kang MS; Moon WS; Yun KJ; Yu ES; Kang H; Kim KM
    Am J Surg Pathol; 2007 Feb; 31(2):224-32. PubMed ID: 17255767
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate.
    Wardelmann E; Merkelbach-Bruse S; Pauls K; Thomas N; Schildhaus HU; Heinicke T; Speidel N; Pietsch T; Buettner R; Pink D; Reichardt P; Hohenberger P
    Clin Cancer Res; 2006 Mar; 12(6):1743-9. PubMed ID: 16551858
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.